House Bill 2685 expands Oregon’s newborn screening and information-sharing framework to address cytomegalovirus (CMV) alongside existing newborn hearing screening requirements. The bill directs the Oregon Health Authority to develop an expanded targeted CMV screening protocol for newborns with symptoms that could be attributed to CMV, to be implemented within 14 days of birth and before discharge from the hospital or birthing center. It also requires hospitals and birthing centers to notify parents and health care providers when a newborn has a positive CMV screening result, and it requires health benefit plans to cover, pay for, or reimburse CMV testing conducted under the new protocol.
The bill amends ORS 433.321 and ORS 433.298 to add CMV-related duties for the Oregon Health Authority, hospitals, birthing centers, diagnostic facilities, prenatal providers, and child care facilities. The authority must publish and distribute information on CMV transmission, symptoms, diagnosis, complications, and treatment, including to prenatal providers and the Department of Early Learning and Care, which must share the information with certified or registered child care facilities. The bill also preserves existing newborn hearing screening rules, reporting obligations, and exemptions, while making the CMV provisions operative only after CMV is added to the state newborn bloodspot screening panel.
The overall sentiment around the bill appears strongly supportive. The measure advanced with broad bipartisan approval, passing the House committee 9-0 on an amended referral, then the House 41-0 and the Senate 29-0. The voting record suggests little public opposition at final passage, and the bill’s focus on early detection, parent notification, and education for providers and families likely contributed to the consensus.
The main policy issue in the bill is how far Oregon should go in requiring CMV screening and related public-health outreach for newborns. The bill creates a targeted screening approach rather than universal screening, and it allows a parent or guardian to object in writing to CMV testing. It also ties implementation to rulemaking by the Oregon Health Authority and to the addition of CMV to the newborn bloodspot panel, which may have been intended to address operational and medical-readiness concerns. No major controversy is reflected in the available transcripts or vote history, but the structure of the screening mandate, the insurance coverage requirement, and the timing of implementation are the most likely points of discussion.
HB 2685 amends Oregon’s newborn screening statutes by adding a CMV-focused screening and education program to the existing newborn hearing screening framework. It imposes new duties on the Oregon Health Authority to adopt rules, publish guidance, and disseminate CMV information; on hospitals and birthing centers to screen, notify, and comply with the protocol; on health benefit plans to cover CMV testing under the protocol; and on child care and early learning entities to receive and share CMV risk information. The bill also preserves existing hearing-screening exemptions and reporting requirements while making the new CMV provisions contingent on future administrative action and bloodspot-panel inclusion.
The bill’s sentiment is broadly favorable and noncontroversial based on the available legislative history. It moved through committee and both chambers with overwhelming support, including unanimous floor votes in the House and Senate. The lack of recorded dissent in final passage suggests the measure was viewed as a public-health improvement focused on early detection, parent notification, and education rather than as a contentious mandate.
No major opposition is evident in the provided record, but the bill’s notable policy choices include requiring insurers to cover CMV testing, directing hospitals and birthing centers to implement a screening protocol, and expanding information-sharing obligations to child care and early learning entities. The bill also allows a written parental objection to CMV testing and delays full operation until the Oregon Health Authority adds CMV to the newborn bloodspot screening panel, reflecting a balance between public-health goals and implementation concerns. Any contention likely centered on how and when screening should be required, rather than on whether CMV is an important health issue.